Renalytix (LON:RENX) Stock Price Down 6.8% – Here’s What Happened

Shares of Renalytix Plc (LON:RENX) traded down 6.8% during trading on Wednesday . The stock traded as low as GBX 2.50 and last traded at GBX 2.61. 630,418 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 883,927 shares. The stock had previously closed at GBX 2.80.

Renalytix Trading Up 4.0%

The firm has a market cap of £11.36 million, a PE ratio of -0.37 and a beta of 1.80. The company’s fifty day moving average price is GBX 4.59 and its two-hundred day moving average price is GBX 6.37. The company has a quick ratio of 2.42, a current ratio of 2.43 and a debt-to-equity ratio of -599.34.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).